世界の非小細胞肺癌(NSCLC)治療薬市場...市場調査レポートについてご紹介

1. Introduction to Non Small Cell Lung Cancer

2. Mechanism of Non Small Cell Lung Cancer Therapeutics

3. Non Small Cell Lung Cancer Therapy Market Overview
3.1 Market Scenario
3.2 Non Small Cell Lung Cancer Pipeline Overview

4. Non Small Cell Lung Cancer Therapy Market Dynamics
4.1 Market Drivers
4.2 Challenges

5. Non Small Cell Lung Cancer Therapy Market Future Prospects

6. Non Small Cell Lung Cancer Drug Pipeline by Phase, Company & Country
6.1 Unknown
6.2 Research
6.3 Preclinical
6.4 Clinical
6.5 Phase-I
6.6 Phase-I/II
6.7 Phase-II
6.8 Phase-II/III
6.9 Phase-III
6.10 Preregistration
6.11 Registered

7. Marketed Non Small Cell Lung Cancer Drugs

8. Suspended & Discontinued Non Small Cell Lung Cancer Drug Pipeline
8.1 No Development Reported
8.2 Discontinued
8.3 Suspended

9. Competitive Landscape
9.1 AstraZeneca
9.2 Biodesix
9.3 Chugai Pharmaceutical
9.4 Eli Lily
9.5 GlaxoSmithKline
9.6 Merck
9.7 Novartis AG
9.8 Pfizer
9.9 Roche
9.10 Transgene

Figure 1-1: Classification of Lung Cancer
Figure 1-2: Treatments Available for NSCLC
Figure 1-3: Categorization of NSCLC on The Basis of Stages
Figure 2-1: Steps Involved in NSCLC Metastasis
Figure 2-2: Mechanism of Tyrosine Kinase Inhibitors
Figure 2-3: Mechanism of Angiogenesis Inhibitors
Figure 2-4: Mode of Action of NSCLC Vaccines
Figure 3-1: Non Small Cell Lung Cancer Pipeline by Phase (%), 2015
Figure 3-2: Non Small Cell Lung Cancer Pipeline by Phase (Number), 2015
Figure 3-3: No Development Reported in Non Small Cell Lung Cancer Pipeline by Phase (%), 2015
Figure 3-4: No Development Reported in Non Small Cell Lung Cancer Pipeline by Phase (Number), 2015
Figure 3-5: Discontinued Non Small Cell Lung Cancer Pipeline by Phase (%), 2015
Figure 3-6: Discontinued Non Small Cell Lung Cancer Pipeline by Phase (%), 2015
Figure 3-7: Suspended Non Small Cell Lung Cancer Pipeline by Phase (%), 2015
Figure 3-8: Suspended Non Small Cell Lung Cancer Pipeline by Phase (Number), 2015